Submitted by Anonymous (not verified) on 30 November 2023 - 13:14
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid, Date of authorisation: 11/02/2021, Revision: 12, Status: Authorised
Source: